GSK PLC Sponsored ADR (NYSE:GSK) Stock Rated “Hold” by Wall Street Brokerages

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have earned a consensus rating of “Hold” from the eleven brokerages that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $56.50.

Several brokerages recently issued reports on GSK. Royal Bank Of Canada assumed coverage on GSK in a report on Tuesday, September 8th. They set a “sector perform” rating for the company. Wall Street Zen cut GSK from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Citigroup initiated coverage on shares of GSK in a report on Friday, July 24th. They set a “neutral” rating on the stock. HSBC reiterated a “hold” rating on shares of GSK in a research note on Thursday, September 10th. Finally, Berenberg Bank set a $60.00 target price on shares of GSK in a report on Tuesday, September 15th.

GSK Trading Down 0.7%

NYSE:GSK opened at $49.38 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. The firm has a 50-day moving average of $50.82 and a 200-day moving average of $52.17. The company has a market cap of $99.87 billion, a PE ratio of 15.44, a PEG ratio of 2.08 and a beta of 0.35. GSK has a one year low of $41.75 and a one year high of $61.69.

GSK (NYSE:GSK) last announced its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. During the same quarter last year, the firm earned $0.47 EPS. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, equities research analysts expect that GSK will post 4.81 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Friday, August 14th will be given a $0.4515 dividend. This represents a $1.81 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date of this dividend is Friday, August 14th. This is a positive change from GSK’s previous quarterly dividend of $0.44. GSK’s payout ratio is currently 55.31%.

Hedge Funds Weigh In On GSK

Hedge funds have recently modified their holdings of the company. NewEdge Advisors LLC grew its holdings in shares of GSK by 842.9% in the second quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after acquiring an additional 852,437 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in GSK by 2,032.8% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 854,331 shares of the pharmaceutical company’s stock worth $41,896,000 after acquiring an additional 814,275 shares during the period. Waverly Advisors LLC lifted its holdings in GSK by 1,372.8% during the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock worth $15,233,000 after acquiring an additional 270,863 shares during the period. Tidal Investments LLC lifted its holdings in GSK by 4.6% during the second quarter. Tidal Investments LLC now owns 220,236 shares of the pharmaceutical company’s stock worth $11,545,000 after acquiring an additional 9,603 shares during the period. Finally, Keystone Financial Planning Inc. boosted its position in GSK by 3,114.8% in the second quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock worth $10,253,000 after purchasing an additional 189,506 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.